Jane Henderson, chief financial officer of Apogee Therapeutics, Inc. (NASDAQ:APGE), reported the sale of 2,000 shares of the company’s common stock on March 25, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at $85.00 apiece, producing a total transaction value of $170,000.
Following the disposition, Henderson directly holds 179,371 shares of Apogee Therapeutics. The filing notes the sale was carried out pursuant to a Rule 10b5-1 trading plan that Henderson adopted on September 2, 2025.
The transaction price was executed close to the stock’s 52-week high of $85.04. Apogee’s shares are currently quoted at $77.89, reflecting a company market capitalization of $5.8 billion. The stock has experienced substantial gains recently, rising 104% over the last six months and up 96% over the past year.
Investor valuation metrics referenced in the filing materials include an InvestingPro analysis that indicates the shares appear overvalued relative to their Fair Value. That analysis is cited alongside broader financial health scores and other metrics available to subscribers of that platform.
Henderson’s sale takes place against a backdrop of active capital markets engagement by Apogee. The company completed a stock offering that generated approximately $403 million in gross proceeds. That transaction involved the sale of 5.75 million common shares at $70 per share and included an option for underwriters to purchase an additional 750,000 shares. Apogee expects net proceeds of roughly $377.4 million after deducting underwriting discounts and related expenses.
These financings follow an earlier announcement of a $350 million stock offering that was also priced at $70 per share. The company has additionally launched a separate public offering valued at $300 million, which carries an option for underwriters to acquire up to an additional $45 million in shares.
Market sentiment around Apogee has been influenced by clinical trial developments. Guggenheim recently raised its price target on Apogee Therapeutics to $160 from $130 while maintaining a Buy rating. The firm cited positive trial data for Apogee’s investigational product zumilokibart, noting that the data demonstrated promising maintenance of responses.
Taken together, the insider sale, the series of public offerings, and the analyst price-target adjustment reflect concurrent developments on corporate governance, capital strategy, and clinical progress for Apogee Therapeutics.